It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to reduce costs and shorten the time it ...

This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy? Veeva Systems markets a suite of software services geared toward the biopharmaceutical industry. A wholly ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two ...

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in ...

Cellarity, a biotechnology company developing cell state-correcting therapies through integrated multi-omics and AI modeling, ...

Google's AI breakthrough in drug discovery suggests novel cancer therapies, highlighting the importance of integrating AI ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

A federal grant for HIV research is part of $15.7 million the National Institutes for Health awarded to the Wertheim UF ...

Malaria is a lethal parasitic infectious disease caused by Plasmodium protozoa. Despite significant advancements in ...